Advanced search
Publication Cover
Scandinavian Journal of Gastroenterology Volume 58, 2023 - Issue 1
Submit an article Journal homepage
1,743
Views
4
CrossRef citations to date
0
Altmetric
Original Article

Therapeutic drug monitoring in inflammatory bowel disease: implementation, utilization, and barriers in clinical practice in Scandinavia

Kristin H. Bjørlykkea Department of Gastroenterology, Akershus University Hospital, Lørenskog, Norway;b Institute of Clinical Medicine, University of Oslo, Oslo, NorwayCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-2369-6760View further author information
ORCID Icon,
Jørgen Jahnsena Department of Gastroenterology, Akershus University Hospital, Lørenskog, Norway;b Institute of Clinical Medicine, University of Oslo, Oslo, NorwayORCID Iconhttps://orcid.org/0000-0002-0419-2914View further author information
ORCID Icon,
Jørn Brynskovc Department of Gastroenterology, Herlev Hospital, Herlev, DenmarkView further author information
,
Pauliina Molanderd Abdominal Center, Gastroenterology, Helsinki University Hospital and University of Helsinki, Helsinki, FinlandView further author information
,
Michael Eberhardsone Department of Gastroenterology, University Hospital, Linköping, Sweden and Karolinska Institutet, Stockholm, SwedenView further author information
,
Loà G. Davidsdottirf Department of Gastroenterology, Landspítali, University Hospital of Iceland, Reykjavik, IcelandView further author information
,
Taina Sipponend Abdominal Center, Gastroenterology, Helsinki University Hospital and University of Helsinki, Helsinki, FinlandView further author information
,
Henrik Hjortswange Department of Gastroenterology, University Hospital, Linköping, Sweden and Karolinska Institutet, Stockholm, SwedenView further author information
,
Guro Løvik Gollg Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, NorwayView further author information
,
Silje Watterdal Syverseng Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, NorwayView further author information
,
Ebbe Langholzc Department of Gastroenterology, Herlev Hospital, Herlev, Denmark;h Institute of Clinical Medicine, University of Copenhagen, Copenhagen, DenmarkView further author information
,
Kristin K. Jørgensena Department of Gastroenterology, Akershus University Hospital, Lørenskog, NorwayView further author information
&
Casper Steenholdtc Department of Gastroenterology, Herlev Hospital, Herlev, DenmarkView further author information
 show all
Pages 25-33 | Received 26 Jun 2022, Accepted 29 Jul 2022, Published online: 23 Aug 2022

Citations (4)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Joel Thunberg, Olle Grännö, Daniel Bergemalm, Carl Eriksson, Isabella Visuri, Michael Eberhardson & Jonas Halfvarson. (2024) Comparative study of a point-of-care test and an enzyme-linked immunosorbent assay (ELISA) for infliximab levels. Scandinavian Journal of Gastroenterology 59:2, pages 150-155.
Read now

Articles from other publishers (3)

Dahham Alsoud, Dirk Jan A. R. Moes, Zhigang Wang, Rani Soenen, Zohra Layegh, Murray Barclay, Tomoyuki Mizuno, Iris K. Minichmayr, Ron J. Keizer, Sebastian G. Wicha, Gertjan Wolbink, Jo Lambert, Séverine Vermeire, Annick de Vries, Konstantinos Papamichael, Núria Padullés-Zamora & Erwin Dreesen. (2024) Best Practice for Therapeutic Drug Monitoring of Infliximab: Position Statement from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. Therapeutic Drug Monitoring.
Crossref
Casper Steenholdt, Ruben Due Lorentsen, Pernille Nørgaard Petersen, Ella SK Widigson, Charlotte Kloft, Rolf Anton Klaasen & Jørn Brynskov. (2024) Therapeutic drug monitoring of vedolizumab therapy in inflammatory bowel disease. Journal of Gastroenterology and Hepatology.
Crossref
Pasqua Letizia Pesole, Marina Liso, Rossella Donghia, Vito Guerra, Antonio Lippolis, Mauro Mastronardi & Palma Aurelia Iacovazzi. (2023) 90K/Mac-2 BP Is a New Predictive Biomarker of Response to Infliximab Therapy in IBD Patients. International Journal of Molecular Sciences 24:4, pages 3955.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.